Posted by Michael Wonder on 14 Aug 2019
FDA grants breakthrough therapy designation for trilaciclib based on myelopreservation data in small cell lung cancer patients
8 August 2019 - G1 Therapeutics today provided a corporate and financial update for the second quarter ended 30 June 2019.
The company has received breakthrough therapy designation from the U.S. FDA based on positive myelopreservation data in small cell lung cancer patients from three randomised Phase 2 clinical trials.
The company expects to submit marketing applications in the U.S. and Europe in 2020.
